-
1
-
-
33646799069
-
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
-
DOI 10.1016/S0140-6736(06)68770-9, PII S0140673606687709
-
Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 May 27; 367 (9524): 1747-57 (Pubitemid 43767064)
-
(2006)
Lancet
, vol.367
, Issue.9524
, pp. 1747-1757
-
-
Lopez, A.D.1
Mathers, C.D.2
Ezzati, M.3
Jamison, D.T.4
Murray, C.J.5
-
2
-
-
34249742714
-
Chronic obstructive pulmonary disease: A growing but neglected global epidemic
-
May
-
Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007 May; 4 (5): e112
-
(2007)
PLoS Med
, vol.4
, Issue.5
-
-
Barnes, P.J.1
-
3
-
-
34548660457
-
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
-
DOI 10.1164/rccm.200703-456SO
-
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176 (6): 532-55 (Pubitemid 47403272)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.6
, pp. 532-555
-
-
Rabe, K.F.1
Hurd, S.2
Anzueto, A.3
Barnes, P.J.4
Buist, S.A.5
Calverley, P.6
Fukuchi, Y.7
Jenkins, C.8
Rodriguez-Roisin, R.9
Van Weel, C.10
Zielinski, J.11
-
4
-
-
34147214922
-
-
Global Initiative for Chronic Obstructive Lung Disease (GOLD) [online] [Accessed 2012 Jun 7]
-
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2011 [online]. Available from URL: http://www.goldcopd.org/[Accessed 2012 Jun 7]
-
(2011)
Global Strategy for the Diagnosis, Management and Prevention of COPD
-
-
-
5
-
-
34548222188
-
Global burden of COPD: risk factors, prevalence, and future trends
-
DOI 10.1016/S0140-6736(07)61380-4, PII S0140673607613804
-
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 Sep 1; 370 (9589): 765-73 (Pubitemid 47321908)
-
(2007)
Lancet
, vol.370
, Issue.9589
, pp. 765-773
-
-
Mannino, D.M.1
Buist, A.S.2
-
6
-
-
0034109837
-
Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease
-
Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 Feb; 161 (2 Pt 1): 342-4 (Pubitemid 30129436)
-
(2000)
American Journal of Respiratory and Critical Care Medicine
, vol.161
, Issue.2
, pp. 342-344
-
-
Barnes, P.J.1
-
7
-
-
69249124565
-
Inhaled corticosteroids in COPD: The case against
-
Jul
-
Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009 Jul; 34 (1): 13-6
-
(2009)
Eur Respir J
, vol.34
, Issue.1
, pp. 13-16
-
-
Suissa, S.1
Barnes, P.J.2
-
8
-
-
0029740875
-
Role of oxidants/antioxidants in smoking-induced lung diseases
-
DOI 10.1016/0891-5849(96)00155-4
-
Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21 (5): 669-81 (Pubitemid 26331096)
-
(1996)
Free Radical Biology and Medicine
, vol.21
, Issue.5
, pp. 669-681
-
-
Rahman, I.1
MacNee, W.2
-
9
-
-
0027410275
-
Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis
-
Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993 Feb; 147 (2): 301-6 (Pubitemid 23044899)
-
(1993)
American Review of Respiratory Disease
, vol.147
, Issue.2
, pp. 301-306
-
-
Saetta, M.1
Di Stefano, A.2
Maestrelli, P.3
Ferraresso, A.4
Drigo, R.5
Potena, A.6
Ciaccia, A.7
Fabbri, L.M.8
-
10
-
-
80052606325
-
Beyond corticosteroids: Future prospects in the management of inflammation in COPD
-
Sep 1
-
Roche N, Marthan R, Berger P, et al. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev 2011 Sep 1; 20 (121): 175-82
-
(2011)
Eur Respir Rev
, vol.20
, Issue.121
, pp. 175-182
-
-
Roche, N.1
Marthan, R.2
Berger, P.3
-
11
-
-
84857722564
-
Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease
-
Mar
-
Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med 2012 Mar; 44 (2): 146-56
-
(2012)
Ann Med
, vol.44
, Issue.2
, pp. 146-156
-
-
Usmani, O.S.1
Barnes, P.J.2
-
12
-
-
0141928029
-
Chronic obstructive pulmonary disease: Molecular and cellular mechanisms
-
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003 Oct; 22 (4): 672-88 (Pubitemid 37258549)
-
(2003)
European Respiratory Journal
, vol.22
, Issue.4
, pp. 672-688
-
-
Barnes, P.J.1
Shapiro, S.D.2
Pauwels, R.A.3
-
13
-
-
53749106584
-
Influence of smoking on airway inflammation and remodelling in asthma
-
Oct
-
St-Laurent J, Bergeron C, Page N, et al. Influence of smoking on airway inflammation and remodelling in asthma. Clin Exp Allergy 2008 Oct; 38 (10): 1582-9
-
(2008)
Clin Exp Allergy
, vol.38
, Issue.10
, pp. 1582-1589
-
-
St-Laurent, J.1
Bergeron, C.2
Page, N.3
-
14
-
-
40049104892
-
Immunology of asthma and chronic obstructive pulmonary disease
-
DOI 10.1038/nri2254, PII NRI2254
-
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. NatRev Immunol 2008Mar; 8 (3): 183-92 (Pubitemid 351323287)
-
(2008)
Nature Reviews Immunology
, vol.8
, Issue.3
, pp. 183-192
-
-
Barnes, P.J.1
-
15
-
-
0034988161
-
Cellular and structural bases of chronic obstructive pulmonary disease
-
Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 May; 163 (6): 1304-9 (Pubitemid 32506590)
-
(2001)
American Journal of Respiratory and Critical Care Medicine
, vol.163
, Issue.6
, pp. 1304-1309
-
-
Saetta, M.1
Turato, G.2
Maestrelli, P.3
Mapp, C.E.4
Fabbri, L.M.5
-
16
-
-
33846813799
-
Influence of cigarette smoke on the arginine pathway in asthmatic airways: Increased expression of arginase I
-
DOI 10.1016/j.jaci.2006.10.030, PII S0091674906022986
-
Bergeron C, Boulet LP, Page N, et al. Influence of cigarette smoke on the arginine pathway in asthmatic airways: increased expression of arginase I. J Allergy Clin Immunol 2007 Feb; 119 (2): 391-7 (Pubitemid 46204814)
-
(2007)
Journal of Allergy and Clinical Immunology
, vol.119
, Issue.2
, pp. 391-397
-
-
Bergeron, C.1
Boulet, L.-P.2
Page, N.3
Laviolette, M.4
Zimmermann, N.5
Rothenberg, M.E.6
Hamid, Q.7
-
17
-
-
0029866161
-
Effects of long-term treatment with corticosteroids in COPD
-
Renkema TE, Schouten JP, Koeter GH, et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996 May; 109 (5): 1156-62 (Pubitemid 26145649)
-
(1996)
Chest
, vol.109
, Issue.5
, pp. 1156-1162
-
-
Renkema, T.E.J.1
Schouten, J.P.2
Koeter, G.H.3
Postma, D.S.4
-
18
-
-
0345188819
-
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
-
DOI 10.1056/NEJM199906243402503
-
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999 Jun 24; 340 (25): 1948-53 (Pubitemid 29288270)
-
(1999)
New England Journal of Medicine
, vol.340
, Issue.25
, pp. 1948-1953
-
-
Pauwels, R.A.1
Lofdahl, C.-G.2
Laitinen, L.A.3
Schouten, J.P.4
Postma, D.S.5
Pride, N.B.6
Ohlsson, S.V.7
-
19
-
-
0034643610
-
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
-
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13; 320 (7245): 1297-303 (Pubitemid 30245717)
-
(2000)
British Medical Journal
, vol.320
, Issue.7245
, pp. 1297-1303
-
-
Burge, P.S.1
Calverley, P.M.A.2
Jones, P.W.3
Spencer, S.4
Anderson, J.A.5
Maslen, T.K.6
-
20
-
-
0033614639
-
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
-
DOI 10.1016/S0140-6736(98)10019-3
-
Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999 May 29; 353 (9167): 1819-23 (Pubitemid 29251012)
-
(1999)
Lancet
, vol.353
, Issue.9167
, pp. 1819-1823
-
-
Vestbo, J.1
Sorensen, T.2
Lange, P.3
Brix, A.4
Tone, P.5
Viskum, K.6
-
21
-
-
0032515756
-
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
-
DOI 10.1016/S0140-6736(97)03471-5
-
Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998 Mar 14; 351 (9105): 773-80 (Pubitemid 28112338)
-
(1998)
Lancet
, vol.351
, Issue.9105
, pp. 773-780
-
-
Paggiaro, P.L.1
Dahle, R.2
Bakran, I.3
Frith, L.4
Hollingworth, K.5
Efthimiou, J.6
-
22
-
-
0038808776
-
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: A meta-analysis
-
Jun 17
-
Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 2003 Jun 17; 138 (12): 969-73
-
(2003)
Ann Intern Med
, vol.138
, Issue.12
, pp. 969-973
-
-
Highland, K.B.1
Strange, C.2
Heffner, J.E.3
-
23
-
-
48949103222
-
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study
-
Aug 15
-
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178 (4): 332-8
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.4
, pp. 332-338
-
-
Celli, B.R.1
Thomas, N.E.2
Anderson, J.A.3
-
24
-
-
34548400452
-
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
-
Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (2): CD002991
-
(2007)
Cochrane Database Syst Rev
, Issue.2
-
-
Yang, I.A.1
Fong, K.M.2
Sim, E.H.3
-
25
-
-
0037111198
-
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The cope study
-
DOI 10.1164/rccm.200206-512OC
-
van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002 Nov 15; 166 (10): 1358-63 (Pubitemid 35292702)
-
(2002)
American Journal of Respiratory and Critical Care Medicine
, vol.166
, Issue.10
, pp. 1358-1363
-
-
Van Valk, P.D.1
Monninkhof, E.2
Van Palen, J.D.3
Zielhuis, G.4
Van Herwaarden, C.5
-
26
-
-
20444497934
-
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: A randomised controlled trial
-
DOI 10.1136/thx.2004.034280
-
Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005 Jun; 60 (6): 480-7 (Pubitemid 40814047)
-
(2005)
Thorax
, vol.60
, Issue.6
, pp. 480-487
-
-
Wouters, E.F.M.1
Postma, D.S.2
Fokkens, B.3
Hop, W.C.J.4
Prins, J.5
Kuipers, A.F.6
Pasma, H.R.7
Hensing, C.A.J.8
Creutzberg, E.C.9
-
27
-
-
77954814658
-
Inhaled corticosteroids in COPD: A controversy
-
Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80 (2): 89-95
-
(2010)
Respiration
, vol.80
, Issue.2
, pp. 89-95
-
-
Barnes, P.J.1
-
28
-
-
13644262558
-
Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment
-
DOI 10.1378/chest.127.2.515
-
Malerba M, Bossoni S, Radaeli A, et al. Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 2005 Feb; 127 (2): 515-21 (Pubitemid 40229311)
-
(2005)
Chest
, vol.127
, Issue.2
, pp. 515-521
-
-
Malerba, M.1
Bossoni, S.2
Radaeli, A.3
Mori, E.4
Bonadonna, S.5
Giustina, A.6
Tantucci, C.7
-
29
-
-
29444460066
-
Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy
-
DOI 10.1016/j.bone.2005.07.002, PII S8756328205002693
-
Malerba M, Bossoni S, Radaeli A, et al. Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy. Bone 2006 Jan; 38 (1): 119-24 (Pubitemid 43008450)
-
(2006)
Bone
, vol.38
, Issue.1
, pp. 119-124
-
-
Malerba, M.1
Bossoni, S.2
Radaeli, A.3
Mori, E.4
Romanelli, G.5
Tantucci, C.6
Giustina, A.7
Grassi, V.8
-
30
-
-
0033542041
-
Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
-
DOI 10.1001/archinte.159.9.941
-
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999 May 10; 159 (9): 941-55 (Pubitemid 29222495)
-
(1999)
Archives of Internal Medicine
, vol.159
, Issue.9
, pp. 941-955
-
-
Lipworth, B.J.1
-
31
-
-
48249085691
-
Cluster analysis and clinical asthma phenotypes
-
Aug 1
-
Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008 Aug 1; 178 (3): 218-24
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.3
, pp. 218-224
-
-
Haldar, P.1
Pavord, I.D.2
Shaw, D.E.3
-
32
-
-
20144382091
-
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease
-
DOI 10.1136/thx.2004.032516
-
Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005 Mar; 60 (3): 193-8 (Pubitemid 40380276)
-
(2005)
Thorax
, vol.60
, Issue.3
, pp. 193-198
-
-
Brightling, C.E.1
McKenna, S.2
Hargadon, B.3
Birring, S.4
Green, R.5
Siva, R.6
Berry, M.7
Parker, D.8
Monteiro, W.9
Pavord, I.D.10
Bradding, P.11
-
33
-
-
80052435472
-
Current controversies and future perspectives in chronic obstructive pulmonary disease
-
Sep 1
-
Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011 Sep 1; 184 (5): 507-13
-
(2011)
Am J Respir Crit Care Med
, vol.184
, Issue.5
, pp. 507-513
-
-
Agusti, A.1
Vestbo, J.2
-
34
-
-
0028264310
-
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
-
DOI 10.1016/S0140-6736(94)92996-3
-
Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994 Jul 23; 344 (8917): 219-24 (Pubitemid 24229008)
-
(1994)
Lancet
, vol.344
, Issue.8917
, pp. 219-224
-
-
Greening, A.P.1
Ind, P.W.2
Northfield, M.3
Shaw, G.4
-
35
-
-
1842370350
-
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group
-
Nov 13
-
Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 Nov 13; 337 (20): 1405-11
-
(1997)
N Engl J Med
, vol.337
, Issue.20
, pp. 1405-1411
-
-
Pauwels, R.A.1
Lofdahl, C.G.2
Postma, D.S.3
-
36
-
-
0032741133
-
Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
-
Nov
-
Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999 Nov; 14 (5): 1038-43
-
(1999)
Eur Respir J
, vol.14
, Issue.5
, pp. 1038-1043
-
-
Juniper, E.F.1
Svensson, K.2
O'Byrne, P.M.3
-
37
-
-
24944482440
-
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy
-
DOI 10.1164/rccm.200408-1041OC
-
Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005 Sep 15; 172 (6): 704-12 (Pubitemid 41324225)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.172
, Issue.6
, pp. 704-712
-
-
Usmani, O.S.1
Ito, K.2
Maneechotesuwan, K.3
Ito, M.4
Johnson, M.5
Barnes, P.J.6
Adcock, I.M.7
-
38
-
-
0037180086
-
2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling
-
DOI 10.1016/S0140-6736(02)11319-5
-
Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002 Oct 26; 360 (9342): 1293-9 (Pubitemid 35284621)
-
(2002)
Lancet
, vol.360
, Issue.9342
, pp. 1293-1299
-
-
Roth, M.1
Johnson, P.R.A.2
Rudiger, J.J.3
King, G.G.4
Ge, Q.5
Burgess, J.K.6
Anderson, G.7
Tamm, M.8
Black, J.L.9
-
39
-
-
33847172367
-
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
-
DOI 10.1056/NEJMoa063070
-
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356 (8): 775-89 (Pubitemid 46294610)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.8
, pp. 775-789
-
-
Calverley, P.M.A.1
Anderson, J.A.2
Celli, B.3
Ferguson, G.T.4
Jenkins, C.5
Jones, P.W.6
Yates, J.C.7
Vestbo, J.8
-
40
-
-
0037108632
-
Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease
-
DOI 10.1164/rccm.2112055
-
Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 Oct 15; 166 (8): 1084-91 (Pubitemid 35178706)
-
(2002)
American Journal of Respiratory and Critical Care Medicine
, vol.166
, Issue.8
, pp. 1084-1091
-
-
Mahler, D.A.1
Wire, P.2
Horstman, D.3
Chang, C.-N.4
Yates, J.5
Fischer, T.6
Shah, T.7
-
41
-
-
0347473812
-
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
-
Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003 Dec; 22 (6): 912-9 (Pubitemid 37540641)
-
(2003)
European Respiratory Journal
, vol.22
, Issue.6
, pp. 912-919
-
-
Calverley, P.M.1
Boonsawat, W.2
Cseke, Z.3
Zhong, N.4
Peterson, S.5
Olsson, H.6
-
42
-
-
33846318149
-
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease
-
DOI 10.1164/rccm.200602-244OC
-
Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jan 15; 175 (2): 144-9 (Pubitemid 46115085)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.175
, Issue.2
, pp. 144-149
-
-
Kardos, P.1
Wencker, M.2
Glaab, T.3
Vogelmeier, C.4
-
43
-
-
47049130249
-
Methodological issues in therapeutic trials of COPD
-
May
-
Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008 May; 31 (5): 927-33
-
(2008)
Eur Respir J
, vol.31
, Issue.5
, pp. 927-933
-
-
Suissa, S.1
Ernst, P.2
Vandemheen, K.L.3
-
44
-
-
34347340694
-
Prevention of death in COPD
-
May 24
-
La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007 May 24; 356 (21): 2211-4
-
(2007)
N Engl J Med
, vol.356
, Issue.21
, pp. 2211-2214
-
-
La Vecchia, C.1
Fabbri, L.M.2
-
45
-
-
40949119305
-
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
-
Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4): CD003794
-
(2007)
Cochrane Database Syst Rev
, Issue.4
-
-
Nannini, L.1
Cates, C.J.2
Lasserson, T.J.3
Poole, P.4
-
46
-
-
70349088498
-
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
-
Sep
-
Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009 Sep; 34 (3): 641-7
-
(2009)
Eur Respir J
, vol.34
, Issue.3
, pp. 641-647
-
-
Crim, C.1
Calverley, P.M.2
Anderson, J.A.3
-
48
-
-
38449105137
-
Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: A pooled analysis
-
DOI 10.1183/09031936.00013006
-
Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007 Sep; 30 (3): 467-71 (Pubitemid 351182069)
-
(2007)
European Respiratory Journal
, vol.30
, Issue.3
, pp. 467-471
-
-
Gamble, E.1
Grootendorst, D.C.2
Hattotuwa, K.3
O'Shaughnessy, T.4
Ram, F.S.F.5
Qiu, Y.6
Zhu, J.7
Vignola, A.M.8
Kroegel, C.9
Morell, F.10
Pavord, I.D.11
Rabe, K.F.12
Jeffery, P.K.13
Barnes, N.C.14
-
50
-
-
0031045482
-
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
-
Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997 Feb; 155 (2): 542-8 (Pubitemid 27085799)
-
(1997)
American Journal of Respiratory and Critical Care Medicine
, vol.155
, Issue.2
, pp. 542-548
-
-
Keatings, V.M.1
Jatakanon, A.2
Worsdell, Y.M.3
Barnes, P.J.4
-
51
-
-
0032696013
-
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease
-
Nov
-
Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Nov; 160 (5 Pt 1): 1635-9
-
(1999)
Am J Respir Crit Care Med
, vol.160
, Issue.5 PART 1
, pp. 1635-1639
-
-
Culpitt, S.V.1
Maziak, W.2
Loukidis, S.3
-
52
-
-
0037097883
-
The effects of inhaled fluticasone on airway inflammation in Chronic Obstructive Pulmonary Disease: A double-blind, placebo-controlled biopsy study
-
DOI 10.1164/rccm.2105025
-
Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebocontrolled biopsy study. Am J Respir Crit Care Med 2002 Jun 15; 165 (12): 1592-6 (Pubitemid 34693937)
-
(2002)
American Journal of Respiratory and Critical Care Medicine
, vol.165
, Issue.12
, pp. 1592-1596
-
-
Hattotuwa, K.L.1
Gizycki, M.J.2
Ansari, T.W.3
Jeffery, P.K.4
Barnes, N.C.5
-
53
-
-
33644784718
-
Corticosteroids: The drugs to beat
-
DOI 10.1016/j.ejphar.2005.12.052, PII S0014299905013816, The Pharmacology of the Respiratory Tract
-
Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006 Mar 8; 533 (1-3): 2-14 (Pubitemid 43340000)
-
(2006)
European Journal of Pharmacology
, vol.533
, Issue.1-3
, pp. 2-14
-
-
Barnes, P.J.1
-
54
-
-
79953726304
-
Glucocorticosteroids: Current and future directions
-
May
-
Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011 May; 163 (1): 29-43
-
(2011)
Br J Pharmacol
, vol.163
, Issue.1
, pp. 29-43
-
-
Barnes, P.J.1
-
55
-
-
77954790495
-
New therapies for chronic obstructive pulmonary disease
-
Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19 (5): 330-8
-
(2010)
Med Princ Pract
, vol.19
, Issue.5
, pp. 330-338
-
-
Barnes, P.J.1
-
56
-
-
77953924437
-
Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients
-
Jun
-
De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010 Jun; 23 (3): 137-48
-
(2010)
J Aerosol Med Pulm Drug Deliv
, vol.23
, Issue.3
, pp. 137-148
-
-
De Backer, W.1
Devolder, A.2
Poli, G.3
-
58
-
-
21044458874
-
Decreased histone deacetylase activity in chronic obstructive pulmonary disease
-
DOI 10.1056/NEJMoa041892
-
Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005 May 12; 352 (19): 1967-76 (Pubitemid 40638367)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.19
, pp. 1967-1976
-
-
Ito, K.1
Ito, M.2
Elliott, W.M.3
Cosio, B.4
Caramori, G.5
Onn, M.K.6
Barczyk, A.7
Hayashi, S.8
Adcock, I.M.9
Hogg, J.C.10
Barnes, P.J.11
-
59
-
-
0033064218
-
Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: No significant effect of cigarette smoking
-
DOI 10.1053/rmed.1999.0574
-
Nowak D, Kasielski M, Antczak A, et al. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med 1999 Jun; 93 (6): 389-96 (Pubitemid 29265348)
-
(1999)
Respiratory Medicine
, vol.93
, Issue.6
, pp. 389-396
-
-
Nowak, D.1
Kasielski, M.2
Antczak, A.3
Pietras, T.4
Bialasiewicz, P.5
-
60
-
-
0842308109
-
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: Role of tyrosine nitration
-
DOI 10.1016/j.bbrc.2004.01.046
-
Ito K, Hanazawa T, Tomita K, et al. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004 Feb 27; 315 (1): 240-5 (Pubitemid 38175212)
-
(2004)
Biochemical and Biophysical Research Communications
, vol.315
, Issue.1
, pp. 240-245
-
-
Ito, K.1
Hanazawa, T.2
Tomita, K.3
Barnes, P.J.4
Adcock, I.M.5
-
61
-
-
65249151877
-
Inhibition of PI3Kdelta restores glucocorticoid function in smokinginduced airway inflammation in mice
-
Apr 1
-
Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smokinginduced airway inflammation in mice. Am J Respir Crit Care Med 2009 Apr 1; 179 (7): 542-8
-
(2009)
Am J Respir Crit Care Med
, vol.179
, Issue.7
, pp. 542-548
-
-
Marwick, J.A.1
Caramori, G.2
Stevenson, C.S.3
-
62
-
-
77958173826
-
Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease
-
Oct 1
-
To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010 Oct 1; 182 (7): 897-904
-
(2010)
Am J Respir Crit Care Med
, vol.182
, Issue.7
, pp. 897-904
-
-
To, Y.1
Ito, K.2
Kizawa, Y.3
-
63
-
-
31344446119
-
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression
-
DOI 10.1084/jem.20050466
-
Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006 Jan 23; 203 (1): 7-13 (Pubitemid 43139638)
-
(2006)
Journal of Experimental Medicine
, vol.203
, Issue.1
, pp. 7-13
-
-
Ito, K.1
Yamamura, S.2
Essilfie-Quaye, S.3
Cosio, B.4
Ito, M.5
Barnes, P.J.6
Adcock, I.M.7
-
64
-
-
2342567291
-
Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients
-
DOI 10.1016/j.jaci.2004.03.018, PII S0091674904011509
-
Matthews JG, Ito K, Barnes PJ, et al. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. JAllergy Clin Immunol 2004 Jun; 113 (6): 1100-8 (Pubitemid 38857992)
-
(2004)
Journal of Allergy and Clinical Immunology
, vol.113
, Issue.6
, pp. 1100-1108
-
-
Matthews, J.G.1
Ito, K.2
Barnes, P.J.3
Adcock, I.M.4
-
65
-
-
0036231010
-
P38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma
-
DOI 10.1067/mai.2002.122465
-
Irusen E, Matthews JG, Takahashi A, et al. p38 Mitogenactivated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002 Apr; 109 (4): 649-57 (Pubitemid 34327193)
-
(2002)
Journal of Allergy and Clinical Immunology
, vol.109
, Issue.4
, pp. 649-657
-
-
Irusen, E.1
Matthews, J.G.2
Takahashi, A.3
Barnes, P.J.4
Chung, K.F.5
Adcock, I.M.6
-
66
-
-
83255187892
-
Ligandindependent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling
-
Dec
-
Galliher-Beckley AJ, Williams JG, Cidlowski JA. Ligandindependent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011 Dec; 31 (23): 4663-75
-
(2011)
Mol Cell Biol
, vol.31
, Issue.23
, pp. 4663-4675
-
-
Galliher-Beckley, A.J.1
Williams, J.G.2
Cidlowski, J.A.3
-
67
-
-
34948900221
-
Steroid receptor phosphorylation: A key modulator of multiple receptor functions
-
DOI 10.1210/me.2007-0101
-
Weigel NL, Moore NL. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 2007 Oct; 21 (10): 2311-9 (Pubitemid 47529347)
-
(2007)
Molecular Endocrinology
, vol.21
, Issue.10
, pp. 2311-2319
-
-
Weigel, N.L.1
Moore, N.L.2
-
68
-
-
33845382332
-
Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells
-
DOI 10.1165/rcmb.2006-0073OC
-
Tao T, Lan J, Lukacs GL, et al. Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. Am J Respir Cell Mol Biol 2006 Dec; 35 (6): 668-80 (Pubitemid 44901856)
-
(2006)
American Journal of Respiratory Cell and Molecular Biology
, vol.35
, Issue.6
, pp. 668-680
-
-
Tao, T.1
Lan, J.2
Lukacs, G.L.3
Hache, R.J.G.4
Kaplan, F.5
-
69
-
-
2342447986
-
Importin 7 and Importin α/Importin β Are Nuclear Import Receptors for the Glucocorticoid Receptor
-
DOI 10.1091/mbc.E03-11-0839
-
Freedman ND, Yamamoto KR. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell 2004 May; 15 (5): 2276-86 (Pubitemid 38580645)
-
(2004)
Molecular Biology of the Cell
, vol.15
, Issue.5
, pp. 2276-2286
-
-
Freedman, N.D.1
Yamamoto, K.R.2
-
70
-
-
42649146208
-
SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease
-
DOI 10.1164/rccm.200708-1269OC
-
Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008 Apr 15; 177 (8): 861-70 (Pubitemid 351600664)
-
(2008)
American Journal of Respiratory and Critical Care Medicine
, vol.177
, Issue.8
, pp. 861-870
-
-
Rajendrasozhan, S.1
Yang, S.-R.2
Kinnula, V.L.3
Rahman, I.4
-
71
-
-
33746674992
-
Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid- resistant asthmatic patients
-
DOI 10.1016/j.jaci.2006.04.055, PII S0091674906010566
-
Loke TK, Mallett KH, Ratoff J, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. JAllergy Clin Immunol 2006 Aug; 118 (2): 368-75 (Pubitemid 44160720)
-
(2006)
Journal of Allergy and Clinical Immunology
, vol.118
, Issue.2
, pp. 368-375
-
-
Loke, T.-K.1
Mallett, K.H.2
Ratoff, J.3
O'Connor, B.J.4
Ying, S.5
Meng, Q.6
Soh, C.7
Lee, T.H.8
Corrigan, C.J.9
-
72
-
-
0028881859
-
Abnormal glucocorticoid receptor-activator protein 1 interaction in steroidresistant asthma
-
Dec 1
-
Adcock IM, Lane SJ, Brown CR, et al. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroidresistant asthma. J ExpMed 1995 Dec 1; 182 (6): 1951-8
-
(1995)
J ExpMed
, vol.182
, Issue.6
, pp. 1951-1958
-
-
Adcock, I.M.1
Lane, S.J.2
Brown, C.R.3
-
73
-
-
4544379912
-
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages
-
DOI 10.1084/jem.20040416
-
Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J ExpMed 2004 Sep 6; 200 (5): 689-95 (Pubitemid 39258317)
-
(2004)
Journal of Experimental Medicine
, vol.200
, Issue.5
, pp. 689-695
-
-
Cosio, B.G.1
Tsaprouni, L.2
Ito, K.3
Jazrawi, E.4
Adcock, I.M.5
Barnes, P.J.6
-
74
-
-
66749146095
-
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: A pilot study
-
May
-
Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009 May; 33 (5): 1010-7
-
(2009)
Eur Respir J
, vol.33
, Issue.5
, pp. 1010-1017
-
-
Spears, M.1
Donnelly, I.2
Jolly, L.3
-
75
-
-
57349099228
-
Emerging pharmacotherapies for COPD
-
Dec
-
Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008 Dec; 134 (6): 1278-86
-
(2008)
Chest
, vol.134
, Issue.6
, pp. 1278-1286
-
-
Barnes, P.J.1
-
76
-
-
33744832661
-
Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy
-
DOI 10.1016/j.pharmthera.2005.10.015, PII S0163725805002767
-
Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006 Aug; 111 (2): 476-94 (Pubitemid 43832007)
-
(2006)
Pharmacology and Therapeutics
, vol.111
, Issue.2
, pp. 476-494
-
-
Kirkham, P.1
Rahman, I.2
-
77
-
-
58549105575
-
Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice
-
Jan 6
-
Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009 Jan 6; 106 (1): 250-5
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.1
, pp. 250-255
-
-
Sussan, T.E.1
Rangasamy, T.2
Blake, D.J.3
-
78
-
-
0040370216
-
Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest
-
DOI 10.1021/bi990842e
-
Zuo Z, Urban G, Scammell JG, et al. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry 1999 Jul 13; 38 (28): 8849-57 (Pubitemid 29334645)
-
(1999)
Biochemistry
, vol.38
, Issue.28
, pp. 8849-8857
-
-
Zuo, Z.1
Urban, G.2
Scammell, J.G.3
Dean, N.M.4
McLean, T.K.5
Aragon, I.6
Honkanen, R.E.7
-
79
-
-
34447095246
-
Phosphoinositide 3-kinase signalling in lung disease: Leucocytes and beyond
-
DOI 10.1111/j.1365-2567.2007.02663.x
-
Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 2007 Aug; 121 (4): 448-61 (Pubitemid 47030097)
-
(2007)
Immunology
, vol.121
, Issue.4
, pp. 448-461
-
-
Medina-Tato, D.A.1
Ward, S.G.2
Watson, M.L.3
-
80
-
-
62449213953
-
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease
-
Mar
-
Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl) pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009 Mar; 328 (3): 758-65
-
(2009)
J Pharmacol Exp Ther
, vol.328
, Issue.3
, pp. 758-765
-
-
Doukas, J.1
Eide, L.2
Stebbins, K.3
-
81
-
-
77951961401
-
Phosphoinositide 3-kinase gamma required for lipopolysaccharide-induced transepithelial neutrophil trafficking in the lung
-
May
-
Reutershan J, Saprito MS, Wu D, et al. Phosphoinositide 3-kinase gamma required for lipopolysaccharide-induced transepithelial neutrophil trafficking in the lung. Eur Respir J 2010 May; 35 (5): 1137-47
-
(2010)
Eur Respir J
, vol.35
, Issue.5
, pp. 1137-1147
-
-
Reutershan, J.1
Saprito, M.S.2
Wu, D.3
-
82
-
-
0037350266
-
Therapeutic potential of phosphoinositide 3-kinase inhibitors
-
DOI 10.1016/S1074-5521(03)00048-6
-
Ward S, Sotsios Y, Dowden J, et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003 Mar; 10 (3): 207-13 (Pubitemid 36380277)
-
(2003)
Chemistry and Biology
, vol.10
, Issue.3
, pp. 207-213
-
-
Ward, S.1
Sotsios, Y.2
Dowden, J.3
Bruce, I.4
Finan, P.5
-
83
-
-
52949103280
-
Can the anti-inflammatory potential of PDE4 inhibitors be realized: Guarded optimism or wishful thinking?
-
Oct
-
Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008 Oct; 155 (3): 288-90
-
(2008)
Br J Pharmacol
, vol.155
, Issue.3
, pp. 288-290
-
-
Giembycz, M.A.1
-
84
-
-
36749063803
-
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
-
DOI 10.1136/thx.2006.075937
-
Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007 Dec; 62 (12): 1081-7 (Pubitemid 350206202)
-
(2007)
Thorax
, vol.62
, Issue.12
, pp. 1081-1087
-
-
Grootendorst, D.C.1
Gauw, S.A.2
Verhoosel, R.M.3
Sterk, P.J.4
Hospers, J.J.5
Bredenbroker, D.6
Bethke, T.D.7
Hiemstra, P.S.8
Rabe, K.F.9
-
85
-
-
34447310046
-
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
-
DOI 10.1164/rccm.200610-1563OC
-
Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jul 15; 176 (2): 154-61 (Pubitemid 47057851)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.2
, pp. 154-161
-
-
Calverley, P.M.A.1
Sanchez-Toril, F.2
McIvor, A.3
Teichmann, P.4
Bredenbroeker, D.5
Fabbri, L.M.6
-
86
-
-
69149098943
-
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials
-
Aug 29
-
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009 Aug 29; 374 (9691): 695-703
-
(2009)
Lancet
, vol.374
, Issue.9691
, pp. 695-703
-
-
Fabbri, L.M.1
Calverley, P.M.2
Izquierdo-Alonso, J.L.3
-
87
-
-
84872219597
-
-
GlaxoSmithKline [ClinicalTrials.gov identifier NCT00549679]. US National Institutes of Health, ClinicalTrials. gov [online] [Accessed 2012 May 3]
-
GlaxoSmithKline. Study to evaluate safety and tolerability of GSK256066 in chronic obstructive pulmonary disease (COPD) patients [ClinicalTrials.gov identifier NCT00549679]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://clin icaltrials.gov [Accessed 2012 May 3]
-
Study to Evaluate Safety and Tolerability of GSK256066 in Chronic Obstructive Pulmonary Disease (COPD) Patients
-
-
-
88
-
-
27644589238
-
Phosphodiesterase-4: Selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease
-
DOI 10.1513/pats.200504-041SR
-
Giembycz MA. Phosphodiesterase-4: selective and dualspecificity inhibitors for the therapy of chronic obstructive pulmonary disease. ProcAmThorac Soc 2005; 2 (4): 326-33; discussion 40-1 (Pubitemid 41566944)
-
(2005)
Proceedings of the American Thoracic Society
, vol.2
, Issue.4
, pp. 326-333
-
-
Giembycz, M.A.1
-
89
-
-
70350345805
-
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
-
Jul
-
Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 2009 Jul; 157 (6): 892-906
-
(2009)
Br J Pharmacol
, vol.157
, Issue.6
, pp. 892-906
-
-
Banner, K.H.1
Press, N.J.2
-
90
-
-
33745939122
-
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl- 2- aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a] isoquinolin-4-one]
-
DOI 10.1124/jpet.105.099192
-
Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6- trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6, 7-tetrahydro-2H- pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6- diisopropylphenoxy)-9,10-dimethoxy-4Hpyrimido[ 6,1-a]isoquino lin-4-one]. J Pharmacol Exp Ther 2006 Aug; 318 (2): 840-8 (Pubitemid 44061259)
-
(2006)
Journal of Pharmacology and Experimental Therapeutics
, vol.318
, Issue.2
, pp. 840-848
-
-
Boswell-Smith, V.1
Spina, D.2
Oxford, A.W.3
Comer, M.B.4
Seeds, E.A.5
Page, C.P.6
-
91
-
-
84863222610
-
Emerging antiinflammatory strategies for chronic obstructive pulmonary disease
-
Epub Apr 10
-
Cazzola M, Page CP, Calzetta L, et al. Emerging antiinflammatory strategies for chronic obstructive pulmonary disease. Eur Respir J. Epub 2012 Apr 10
-
(2012)
Eur Respir J.
-
-
Cazzola, M.1
Page, C.P.2
Calzetta, L.3
-
92
-
-
44649153952
-
Increased activation of p38 MAPK in COPD
-
Jan
-
Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008 Jan; 31 (1): 62-9
-
(2008)
Eur Respir J
, vol.31
, Issue.1
, pp. 62-69
-
-
Renda, T.1
Baraldo, S.2
Pelaia, G.3
-
93
-
-
40849119969
-
P38α-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation
-
DOI 10.1124/jpet.107.127092
-
Medicherla S, Fitzgerald MF, Spicer D, et al. p38alphaselective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008 Mar; 324 (3): 921-9 (Pubitemid 351397845)
-
(2008)
Journal of Pharmacology and Experimental Therapeutics
, vol.324
, Issue.3
, pp. 921-929
-
-
Medicherla, S.1
Fitzgerald, M.F.2
Spicer, D.3
-
94
-
-
84860172730
-
An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease
-
Mar
-
Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012 Mar; 52 (3): 416-24
-
(2012)
J Clin Pharmacol
, vol.52
, Issue.3
, pp. 416-424
-
-
Lomas, D.A.1
Lipson, D.A.2
Miller, B.E.3
-
95
-
-
79958710208
-
P38 mitogen-activated protein kinase pathways in asthma and COPD
-
Jun
-
Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011 Jun; 139 (6): 1470-9
-
(2011)
Chest
, vol.139
, Issue.6
, pp. 1470-1479
-
-
Chung, K.F.1
-
96
-
-
33745153836
-
IκB kinase-2-independent and -dependent inflammation in airway disease models: Relevance of IKK-2 inhibition to the clinic
-
DOI 10.1124/mol.105.019521
-
Birrell MA, Wong S, Hardaker EL, et al. IkappaB kinase-2-independent and-dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006 Jun; 69 (6): 1791-800 (Pubitemid 43894295)
-
(2006)
Molecular Pharmacology
, vol.69
, Issue.6
, pp. 1791-1800
-
-
Birrell, M.A.1
Wong, S.2
Hardaker, E.L.3
Catley, M.C.4
McCluskie, K.5
Collins, M.6
Haj-Yahia, S.7
Belvisi, M.G.8
-
97
-
-
33846411054
-
Inhibition of tumor necrosis factor-α-inducible inflammatory genes by interferon-γ is associated with altered nuclear factor-κB transactivation and enhanced histone deacetylase activity
-
DOI 10.1124/mol.106.030171
-
Keslacy S, Tliba O, Baidouri H, et al. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol 2007 Feb; 71 (2): 609-18 (Pubitemid 46147925)
-
(2007)
Molecular Pharmacology
, vol.71
, Issue.2
, pp. 609-618
-
-
Keslacy, S.1
Tliba, O.2
Baidouri, H.3
Amrani, Y.4
-
98
-
-
33746217403
-
Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle
-
DOI 10.1124/mol.106.023150
-
Catley MC, Sukkar MB, Chung KF, et al. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviralmediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006 Aug; 70 (2): 697-705 (Pubitemid 44092330)
-
(2006)
Molecular Pharmacology
, vol.70
, Issue.2
, pp. 697-705
-
-
Catley, M.C.1
Sukkar, M.B.2
Chung, K.F.3
Jaffee, B.4
Liao, S.-M.5
Coyle, A.J.6
Haddad, E.-B.7
Barnes, P.J.8
Newton, R.9
-
99
-
-
33748580720
-
Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease
-
DOI 10.1016/j.tips.2006.08.001, PII S0165614706001817
-
Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006 Oct; 27 (10): 546-53 (Pubitemid 44374756)
-
(2006)
Trends in Pharmacological Sciences
, vol.27
, Issue.10
, pp. 546-553
-
-
Donnelly, L.E.1
Barnes, P.J.2
-
100
-
-
38349077242
-
CXCR3 and CCR5 chemokines in induced sputum from patients with COPD
-
Jan
-
Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008 Jan; 133 (1): 26-33
-
(2008)
Chest
, vol.133
, Issue.1
, pp. 26-33
-
-
Costa, C.1
Rufino, R.2
Traves, S.L.3
-
101
-
-
34247607712
-
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease
-
DOI 10.1164/rccm.200607-995OC
-
Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 May 1; 175 (9): 926-34 (Pubitemid 46684703)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.175
, Issue.9
, pp. 926-934
-
-
Rennard, S.I.1
Fogarty, C.2
Kelsen, S.3
Long, W.4
Ramsdell, J.5
Allison, J.6
Mahler, D.7
Saadeh, C.8
Siler, T.9
Snell, P.10
Korenblat, P.11
Smith, W.12
Kaye, M.13
Mandel, M.14
Andrews, C.15
Prabhu, R.16
Donohue, J.F.17
Watt, R.18
Kim, H.L.19
Schlenker-Herceg, R.20
Barnathan, E.S.21
Murray, J.22
more..
-
102
-
-
33750102235
-
Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders
-
DOI 10.1358/dot.2006.42.9.1025692
-
Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 2006 Sep; 42 (9): 559-76 (Pubitemid 44595080)
-
(2006)
Drugs of Today
, vol.42
, Issue.9
, pp. 559-576
-
-
Paul-Pletzer, K.1
-
105
-
-
34547815598
-
Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs
-
DOI 10.1136/thx.2006.068353
-
ChurgA,WangR,WangX, et al. Effect of anMMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007 Aug; 62 (8): 706-13 (Pubitemid 47235016)
-
(2007)
Thorax
, vol.62
, Issue.8
, pp. 706-713
-
-
Churg, A.1
Wang, R.2
Wang, X.3
Onnervik, P.-O.4
Thim, K.5
Wright, J.L.6
|